ArticleBMC complementary medicine and therapies2025
A standardized extract of Centella asiatica (ECa 233) alleviates brain injury and improves brain function in β-thalassemia mice with iron overload.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron overload plays a role in the pathogenesis of neurodegenerative disorders by inducing oxidative injury in the brain. Centella asiatica (L.) Urb. It is a medicinal plant with neuroprotective effects that exhibits antioxidant and anti-inflammatory activities. A standardized extract of C. asiatica (ECa 233) has high concentrations of the bioactive compounds madecassoside and asiaticoside. It may have potential for use in iron overload conditions.
objectivesThis study aimed to investigate the effects of ECa 233 on iron-induced brain injury, memory deficits, and impaired locomotor activity in 12-month-old wild-type (WT) and β-thalassemia (β-globin knockout, BKO) mice with iron overload.
methodsWT and BKO mice were intraperitoneally (i.p.) injected with 100 mg of iron, followed by i.p. injection of 20 mg/kg body weight of ECa 233 for 10 days. Iron accumulation and injury in the brain were evaluated via hematoxylin and eosin (H&E) and Prussian blue staining. The Morris water maze (MWM) and open field tests were performed to evaluate spatial learning and memory and locomotor activity, respectively.
resultsAging BKO mice resulted in spontaneous iron accumulation in the brain and poor performance in the MWM test. Iron overload significantly increased brain iron content and worsened brain injury, locomotor activity, and performance in the MWM test in both WT and BKO mice. Treatment with ECa 233 significantly decreased iron accumulation in the brain and reversed brain damage in WT and BKO mice to the same extent. In addition, ECa 233 improved iron-induced memory deficits in WT mice and locomotor activity in iron-overloaded WT and BKO mice.
conclusionThese results suggest that the beneficial effect of ECa 233 may be partially due to decreased iron accumulation in the brain. ECa 233 may be used as an adjuvant with an iron chelator to prevent iron-induced neurodegenerative complications in individuals with β-thalassemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.